Table 1.

Clinicopathologic characteristics of two sets of CRC patients according to the two-miRNAs signature

		Training set (n = 67)				Internal testing set (n = 40)				Independent validation set (n = 44)
Characteristics	No.	Low risk (%)	High risk (%)	p value	No	Low risk (%)	High risk (%)	p value	No.	Low risk (%)	High risk (%)	p value
Gender				0.68				0.35				0.60
Male	42	18 (42.9)	24 (57.1)		25	17 (68.0)	8 (32.0)		27	18 (66.7)	9 (33.3)
Female	25	12 (48.0)	13 (52.0)		15	8 (53.3)	7 (46.7)		17	10 (58.8)	7 (41.2)
Age				0.09				0.62				0.16
<60-year-old	41	15 (36.6)	26 (63.4)		22	13 (68.4)	9 (31.6)		28	20 (71.4)	8 (28.6)
≥60-year-old	26	15 (57.7)	11 (42.3)		18	12 (66.7)	6 (33.3)		16	8 (50.0)	8 (50.0)
Tumour location				0.14				0.67				0.72
Colon	50	25 (50.0)	25 (50.0)		25	15 (60.0)	10 (40.0)		29	19 (65.5)	10 (34.5)
Rectum	17	5 (29.4)	12 (70.6)		15	10 (66.7)	5 (33.3)		15	9 (66.7)	6 (33.3)
Tumour grade				0.35				0.55				0.70
Low	6	1 (16.7)	5 (83.3)		3	1 (33.3)	2 (66.7)		5	4 (80.0)	1 (20.0)
Median	57	27 (47.4)	30 (52.6)		34	22 (64.7)	12 (35.3)		38	23 (60.5)	15 (39.5)
High	4	2 (50.0)	2 (50.0)		3	2 (66.7)	1 (33.3)		1	1 (100.0)	0 (0.0)
Metastatic location				0.68				0.57				0.63
Liver	42	18 (42.9)	24 (57.1)		30	18 (60.0)	12 (40.0)		34	21 (61.8)	13 (38.2)
Others	25	12 (48.0)	13 (52.0)		10	7 (70.0)	3 (30.0)		10	7 (70.0)	3 (30.0)
Metastatic type				0.82				0.43				0.91
Synchronous	50	22 (44.0)	28 (56.0)		27	18 (66.7)	9 (33.3)		27	17 (63.0)	10 (27.0)
Metachronous	17	8 (47.1)	9 (52.9)		13	7 (53.8)	6 (46.2)		17	11 (64.7)	6 (35.3)
Chemotherapy strategy				0.69				0.28				0.91
FOLFOX	55	24 (43.6)	31 (56.4)		31	18 (58.0)	13 (42.0)		27	17 (63.0)	10 (27.0)
FOLFIRI	12	6 (50.0)	6 (50.0)		9	7 (77.8)	2 (22.2)		17	11 (64.7)	6 (35.3)
Response for chemotherapy				<0.001				<0.001				<0.001
CR + PR	23	15 (65.2)	8 (34.8)		10	9 (90.0)	1 (10.0)		11	6 (54.5)	5 (45.5)
SD	31	11 (35.5)	20 (64.5)		21	13 (61.9)	8 (38.1)		21	17 (81.0)	4 (19.0)
PD	13	4 (30.8)	9 (69.2)		9	3 (33.3)	6 (66.7)		12	5 (41.7)	7 (58.3)